Study #2015-0856
Phase I Trial of Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma
MD Anderson Study Status
Not Accepting
Treatment Agent
Pembrolizumab
Description
This phase I trial studies the side effects and best way to give pembrolizumab after radiation therapy in treating patients with pleural malignant mesothelioma. Radiation therapy uses high energy radiation to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab after radiation therapy may kill more tumor cells.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Pleural Malignant Mesothelioma
Study phase:
Phase I
Physician name:
Matthew Ning
Department:
Radiation Oncology
For general questions about clinical trials:
1-844-577-0738
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.